Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL2846 + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral (AL2846), Intravenous (gemcitabine)
01
Overview
AL2846 + gemcitabine is a combination therapy consisting of AL2846, an investigational oral multi-target tyrosine kinase inhibitor (TKI) with potent inhibition of multiple receptor tyrosine kinases including **c-MET, VEGFR1, VEGFR3, c-KIT, Axl, RET, and KDR**, and gemcitabine, a nucleoside analog and antineoplastic chemotherapy agent. This combination has been primarily evaluated in advanced pancreatic cancer. AL2846 is designed to target molecular pathways involved in tumor growth, angiogenesis, and drug resistance, while gemcitabine is a standard cytotoxic agent used in various solid tumors. Clinical studies show the combination is tolerated but does not improve efficacy over standard treatment in pancreatic cancer[1][3][9].
- Brand names
- Gemzar
02
Targets
AXL (AXL receptor tyrosine kinase)DNA polymerase familyKIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on AL2846 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL2846 + gemcitabine.